Two groups of bariatric surgeons want to expand eligibility for weight loss surgery. Whether insurance companies will agree remains to be seen.
Author: Karen Weintraub, USA TODAY
A new treatment is restoring skin coloration to some with vitiligo. It’s giving patients hope.
A new study shows a treatment for vitiligo, which recently won FDA approval, restores natural skin color to one-third of patients.
For patients with earliest stage of breast cancer, how much treatment is enough?
Doctors are getting better at figuring out who with the earliest stage of breast cancer needs aggressive treatment and who can get less care.
These rats have human cells in their brains. They may help scientists understand autism and schizophrenia.
Stanford researcher Sergiu Pașca’s experiments, published Wednesday in the journal Nature, are both significant and ethically challenging.
FDA approves Relyvrio, the first new ALS drug in five years. Patients had wanted it sooner.
The Food and Drug Administration on Thursday approved the use of Relyvrio to treat amyotrophic lateral sclerosis, more commonly known as ALS.
‘Food as medicine’: White House pilot program would bring medically tailored meals under Medicare
Medically tailored meals are one of many new programs proposed Tuesday by the Biden administration to reduce hunger and diet-related diseases.
‘Extraordinary’ study results offer new hope for advanced lung cancer patients being treated with immunotherapy
New studies quantify the duration and magnitude of immunotherapy benefits for advanced lung cancer patients.
CDC panel clears way for new COVID boosters for all Americans over 12
The CDC expert panel recommendation paves the way for reformulated COVID-19 booster shots to be available in the coming days.
FDA authorizes reformulated COVID-19 booster shot for the fall
The new booster shots could be available within days, after a CDC committee on Thursday recommends who should get them and its director signs off.
Seeking vaccine against Lyme disease, Pfizer and French partner Valneva launch major trial
The trial will enroll about 6,000 volunteers, ages 5 and up, at as many as 50 worldwide sites where Lyme disease is a problem, including the U.S.